Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2

Roni Mamluk, Irvith M. Carvajal, Brent A. Morse, Henry Wong, Janette Abramowitz, Sharon Aslanian, Ai Ching Lim, Jochem Gokemeijer, Michael J. Storek, Joonsoo Lee, Michael Gosselin, Martin C. Wright, Ray T. Camphausen, Jack Wang, Yan Chen, Kathy Miller, Kerry Sanders, Sarah Short, Jeff Sperinde, Gargi Prasad & 7 others Stephen Williams, Robert Kerbel, John Ebos, Anthony Mutsaers, John D. Mendlein, Alan S. Harris, Eric S. Furfine

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Ct-322 is a new anti-angiogenic therapeutic agent based on an engineered variant of the tenth type III domain of human fibronectin, i.e., an AdnectintM, designed to inhibit vascular endothelial growth factor receptor (VeGFR)-2. this peGylated Adnectin was developed using an mRNA display technology. Ct-322 bound human VeGFR-2 with high affi nity (KD, 11 nM), but did not bind VeGFR-1 or VeGFR-3 at concentrations up to 100 nM, as determined by surface plasmon resonance studies. Western blot analysis showed that Ct-322 blocked VeGF-induced phosphorylation of VeGFR-2 and mitogenactivated protein kinase in human umbilical vascular endothelial cells. Ct-322 significantly inhibited the growth of human tumor xenograft models of colon carcinoma and glioblastoma at doses of 15-60 mg/kg administered 3 times/week. Anti-tumor effects of Ct-322 were comparable to those of sorafenib or sunitinib, which inhibit multiple kinases, in a colon carcinoma xenograft model, although Ct-322 caused less overt adverse effects than the kinase inhibitors. Ct-322 also enhanced the anti-tumor activity of the chemotherapeutic agent temsirolimus in the colon carcinoma model. the high affi nity and specificity of Ct-322 binding to VeGFR-2 and its anti-tumor activities establish Ct-322 as a promising anti-angiogenic therapeutic agent. our results further suggest that Adnectins are an important new class of targeted biologics that can be developed as potential treatments for a wide variety of diseases.

Original languageEnglish
Pages (from-to)199-208
Number of pages10
JournalmAbs
Volume2
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

Vascular Endothelial Growth Factor Receptor-2
Colon
Carcinoma
Heterografts
Neoplasms
Phosphotransferases
Vascular Endothelial Growth Factor Receptor-3
Vascular Endothelial Growth Factor Receptor-1
Umbilicus
Surface Plasmon Resonance
Glioblastoma
Biological Products
Protein Kinases
Vascular Endothelial Growth Factor A
Endothelial Cells
Western Blotting
Phosphorylation
Technology
Messenger RNA
CT-322

Keywords

  • Adnectin
  • Angiogenesis inhibitor
  • Biologics
  • CT-322
  • Targeted therapy
  • Tumor angiogenesis
  • VEGFR-2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Mamluk, R., Carvajal, I. M., Morse, B. A., Wong, H., Abramowitz, J., Aslanian, S., ... Furfine, E. S. (2010). Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. mAbs, 2(2), 199-208. https://doi.org/10.4161/mabs.2.2.11304

Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. / Mamluk, Roni; Carvajal, Irvith M.; Morse, Brent A.; Wong, Henry; Abramowitz, Janette; Aslanian, Sharon; Lim, Ai Ching; Gokemeijer, Jochem; Storek, Michael J.; Lee, Joonsoo; Gosselin, Michael; Wright, Martin C.; Camphausen, Ray T.; Wang, Jack; Chen, Yan; Miller, Kathy; Sanders, Kerry; Short, Sarah; Sperinde, Jeff; Prasad, Gargi; Williams, Stephen; Kerbel, Robert; Ebos, John; Mutsaers, Anthony; Mendlein, John D.; Harris, Alan S.; Furfine, Eric S.

In: mAbs, Vol. 2, No. 2, 03.2010, p. 199-208.

Research output: Contribution to journalArticle

Mamluk, R, Carvajal, IM, Morse, BA, Wong, H, Abramowitz, J, Aslanian, S, Lim, AC, Gokemeijer, J, Storek, MJ, Lee, J, Gosselin, M, Wright, MC, Camphausen, RT, Wang, J, Chen, Y, Miller, K, Sanders, K, Short, S, Sperinde, J, Prasad, G, Williams, S, Kerbel, R, Ebos, J, Mutsaers, A, Mendlein, JD, Harris, AS & Furfine, ES 2010, 'Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2', mAbs, vol. 2, no. 2, pp. 199-208. https://doi.org/10.4161/mabs.2.2.11304
Mamluk R, Carvajal IM, Morse BA, Wong H, Abramowitz J, Aslanian S et al. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. mAbs. 2010 Mar;2(2):199-208. https://doi.org/10.4161/mabs.2.2.11304
Mamluk, Roni ; Carvajal, Irvith M. ; Morse, Brent A. ; Wong, Henry ; Abramowitz, Janette ; Aslanian, Sharon ; Lim, Ai Ching ; Gokemeijer, Jochem ; Storek, Michael J. ; Lee, Joonsoo ; Gosselin, Michael ; Wright, Martin C. ; Camphausen, Ray T. ; Wang, Jack ; Chen, Yan ; Miller, Kathy ; Sanders, Kerry ; Short, Sarah ; Sperinde, Jeff ; Prasad, Gargi ; Williams, Stephen ; Kerbel, Robert ; Ebos, John ; Mutsaers, Anthony ; Mendlein, John D. ; Harris, Alan S. ; Furfine, Eric S. / Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. In: mAbs. 2010 ; Vol. 2, No. 2. pp. 199-208.
@article{7000cbe0b2e241678bc4747c1aed2907,
title = "Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2",
abstract = "Ct-322 is a new anti-angiogenic therapeutic agent based on an engineered variant of the tenth type III domain of human fibronectin, i.e., an AdnectintM, designed to inhibit vascular endothelial growth factor receptor (VeGFR)-2. this peGylated Adnectin was developed using an mRNA display technology. Ct-322 bound human VeGFR-2 with high affi nity (KD, 11 nM), but did not bind VeGFR-1 or VeGFR-3 at concentrations up to 100 nM, as determined by surface plasmon resonance studies. Western blot analysis showed that Ct-322 blocked VeGF-induced phosphorylation of VeGFR-2 and mitogenactivated protein kinase in human umbilical vascular endothelial cells. Ct-322 significantly inhibited the growth of human tumor xenograft models of colon carcinoma and glioblastoma at doses of 15-60 mg/kg administered 3 times/week. Anti-tumor effects of Ct-322 were comparable to those of sorafenib or sunitinib, which inhibit multiple kinases, in a colon carcinoma xenograft model, although Ct-322 caused less overt adverse effects than the kinase inhibitors. Ct-322 also enhanced the anti-tumor activity of the chemotherapeutic agent temsirolimus in the colon carcinoma model. the high affi nity and specificity of Ct-322 binding to VeGFR-2 and its anti-tumor activities establish Ct-322 as a promising anti-angiogenic therapeutic agent. our results further suggest that Adnectins are an important new class of targeted biologics that can be developed as potential treatments for a wide variety of diseases.",
keywords = "Adnectin, Angiogenesis inhibitor, Biologics, CT-322, Targeted therapy, Tumor angiogenesis, VEGFR-2",
author = "Roni Mamluk and Carvajal, {Irvith M.} and Morse, {Brent A.} and Henry Wong and Janette Abramowitz and Sharon Aslanian and Lim, {Ai Ching} and Jochem Gokemeijer and Storek, {Michael J.} and Joonsoo Lee and Michael Gosselin and Wright, {Martin C.} and Camphausen, {Ray T.} and Jack Wang and Yan Chen and Kathy Miller and Kerry Sanders and Sarah Short and Jeff Sperinde and Gargi Prasad and Stephen Williams and Robert Kerbel and John Ebos and Anthony Mutsaers and Mendlein, {John D.} and Harris, {Alan S.} and Furfine, {Eric S.}",
year = "2010",
month = "3",
doi = "10.4161/mabs.2.2.11304",
language = "English",
volume = "2",
pages = "199--208",
journal = "mAbs",
issn = "1942-0862",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2

AU - Mamluk, Roni

AU - Carvajal, Irvith M.

AU - Morse, Brent A.

AU - Wong, Henry

AU - Abramowitz, Janette

AU - Aslanian, Sharon

AU - Lim, Ai Ching

AU - Gokemeijer, Jochem

AU - Storek, Michael J.

AU - Lee, Joonsoo

AU - Gosselin, Michael

AU - Wright, Martin C.

AU - Camphausen, Ray T.

AU - Wang, Jack

AU - Chen, Yan

AU - Miller, Kathy

AU - Sanders, Kerry

AU - Short, Sarah

AU - Sperinde, Jeff

AU - Prasad, Gargi

AU - Williams, Stephen

AU - Kerbel, Robert

AU - Ebos, John

AU - Mutsaers, Anthony

AU - Mendlein, John D.

AU - Harris, Alan S.

AU - Furfine, Eric S.

PY - 2010/3

Y1 - 2010/3

N2 - Ct-322 is a new anti-angiogenic therapeutic agent based on an engineered variant of the tenth type III domain of human fibronectin, i.e., an AdnectintM, designed to inhibit vascular endothelial growth factor receptor (VeGFR)-2. this peGylated Adnectin was developed using an mRNA display technology. Ct-322 bound human VeGFR-2 with high affi nity (KD, 11 nM), but did not bind VeGFR-1 or VeGFR-3 at concentrations up to 100 nM, as determined by surface plasmon resonance studies. Western blot analysis showed that Ct-322 blocked VeGF-induced phosphorylation of VeGFR-2 and mitogenactivated protein kinase in human umbilical vascular endothelial cells. Ct-322 significantly inhibited the growth of human tumor xenograft models of colon carcinoma and glioblastoma at doses of 15-60 mg/kg administered 3 times/week. Anti-tumor effects of Ct-322 were comparable to those of sorafenib or sunitinib, which inhibit multiple kinases, in a colon carcinoma xenograft model, although Ct-322 caused less overt adverse effects than the kinase inhibitors. Ct-322 also enhanced the anti-tumor activity of the chemotherapeutic agent temsirolimus in the colon carcinoma model. the high affi nity and specificity of Ct-322 binding to VeGFR-2 and its anti-tumor activities establish Ct-322 as a promising anti-angiogenic therapeutic agent. our results further suggest that Adnectins are an important new class of targeted biologics that can be developed as potential treatments for a wide variety of diseases.

AB - Ct-322 is a new anti-angiogenic therapeutic agent based on an engineered variant of the tenth type III domain of human fibronectin, i.e., an AdnectintM, designed to inhibit vascular endothelial growth factor receptor (VeGFR)-2. this peGylated Adnectin was developed using an mRNA display technology. Ct-322 bound human VeGFR-2 with high affi nity (KD, 11 nM), but did not bind VeGFR-1 or VeGFR-3 at concentrations up to 100 nM, as determined by surface plasmon resonance studies. Western blot analysis showed that Ct-322 blocked VeGF-induced phosphorylation of VeGFR-2 and mitogenactivated protein kinase in human umbilical vascular endothelial cells. Ct-322 significantly inhibited the growth of human tumor xenograft models of colon carcinoma and glioblastoma at doses of 15-60 mg/kg administered 3 times/week. Anti-tumor effects of Ct-322 were comparable to those of sorafenib or sunitinib, which inhibit multiple kinases, in a colon carcinoma xenograft model, although Ct-322 caused less overt adverse effects than the kinase inhibitors. Ct-322 also enhanced the anti-tumor activity of the chemotherapeutic agent temsirolimus in the colon carcinoma model. the high affi nity and specificity of Ct-322 binding to VeGFR-2 and its anti-tumor activities establish Ct-322 as a promising anti-angiogenic therapeutic agent. our results further suggest that Adnectins are an important new class of targeted biologics that can be developed as potential treatments for a wide variety of diseases.

KW - Adnectin

KW - Angiogenesis inhibitor

KW - Biologics

KW - CT-322

KW - Targeted therapy

KW - Tumor angiogenesis

KW - VEGFR-2

UR - http://www.scopus.com/inward/record.url?scp=77951544346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951544346&partnerID=8YFLogxK

U2 - 10.4161/mabs.2.2.11304

DO - 10.4161/mabs.2.2.11304

M3 - Article

VL - 2

SP - 199

EP - 208

JO - mAbs

JF - mAbs

SN - 1942-0862

IS - 2

ER -